PMC:7534795 / 39597-46304
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T184 | 134-137 | Body_part | denotes | arm | http://purl.org/sig/ont/fma/fma24890 |
| T185 | 338-343 | Body_part | denotes | organ | http://purl.org/sig/ont/fma/fma67498 |
| T186 | 367-375 | Body_part | denotes | capsules | http://purl.org/sig/ont/fma/fma85272 |
| T187 | 400-405 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T188 | 535-543 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T189 | 565-570 | Body_part | denotes | organ | http://purl.org/sig/ont/fma/fma67498 |
| T190 | 1216-1219 | Body_part | denotes | arm | http://purl.org/sig/ont/fma/fma24890 |
| T191 | 1361-1366 | Body_part | denotes | organ | http://purl.org/sig/ont/fma/fma67498 |
| T192 | 1520-1528 | Body_part | denotes | Cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T193 | 1671-1680 | Body_part | denotes | cytokines | http://purl.org/sig/ont/fma/fma84050 |
| T194 | 1974-1983 | Body_part | denotes | melatonin | http://purl.org/sig/ont/fma/fma74644 |
| T195 | 2092-2101 | Body_part | denotes | Melatonin | http://purl.org/sig/ont/fma/fma74644 |
| T196 | 2359-2367 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T197 | 2875-2886 | Body_part | denotes | interleukin | http://purl.org/sig/ont/fma/fma86578 |
| T198 | 2898-2906 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T199 | 2964-2972 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T200 | 3009-3013 | Body_part | denotes | IL-1 | http://purl.org/sig/ont/fma/fma86583 |
| T201 | 3463-3471 | Body_part | denotes | Cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T202 | 3646-3651 | Body_part | denotes | serum | http://purl.org/sig/ont/fma/fma63083 |
| T203 | 4877-4885 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T204 | 5273-5278 | Body_part | denotes | organ | http://purl.org/sig/ont/fma/fma67498 |
| T205 | 5663-5673 | Body_part | denotes | fatty acid | http://purl.org/sig/ont/fma/fma82738 |
| T206 | 5778-5786 | Body_part | denotes | capsules | http://purl.org/sig/ont/fma/fma85272 |
| T207 | 6033-6043 | Body_part | denotes | fatty acid | http://purl.org/sig/ont/fma/fma82738 |
| T208 | 6075-6083 | Body_part | denotes | capsules | http://purl.org/sig/ont/fma/fma85272 |
| T209 | 6176-6184 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T210 | 6378-6393 | Body_part | denotes | coronary artery | http://purl.org/sig/ont/fma/fma49893 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T66 | 134-137 | Body_part | denotes | arm | http://purl.obolibrary.org/obo/UBERON_0001460 |
| T67 | 338-343 | Body_part | denotes | organ | http://purl.obolibrary.org/obo/UBERON_0000062 |
| T68 | 565-570 | Body_part | denotes | organ | http://purl.obolibrary.org/obo/UBERON_0000062 |
| T69 | 1216-1219 | Body_part | denotes | arm | http://purl.obolibrary.org/obo/UBERON_0001460 |
| T70 | 1361-1366 | Body_part | denotes | organ | http://purl.obolibrary.org/obo/UBERON_0000062 |
| T71 | 3646-3651 | Body_part | denotes | serum | http://purl.obolibrary.org/obo/UBERON_0001977 |
| T72 | 3963-3968 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
| T73 | 5273-5278 | Body_part | denotes | organ | http://purl.obolibrary.org/obo/UBERON_0000062 |
| T74 | 6378-6393 | Body_part | denotes | coronary artery | http://purl.obolibrary.org/obo/UBERON_0001621 |
| T75 | 6387-6393 | Body_part | denotes | artery | http://purl.obolibrary.org/obo/UBERON_0001637 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T317 | 187-195 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T318 | 822-829 | Disease | denotes | sterile | http://purl.obolibrary.org/obo/MONDO_0005047 |
| T319 | 1947-1955 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T320 | 2324-2332 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T321 | 3441-3449 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T322 | 3450-3460 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T323 | 3472-3486 | Disease | denotes | storm syndrome | http://purl.obolibrary.org/obo/MONDO_0008496 |
| T324 | 3733-3742 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T325 | 3813-3835 | Disease | denotes | hospitalized infection | http://purl.obolibrary.org/obo/MONDO_0043544 |
| T326 | 3826-3835 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T327 | 4351-4359 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T328 | 4360-4369 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
| T329 | 4522-4530 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T330 | 4626-4634 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T331 | 5122-5125 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
| T332 | 5156-5164 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T333 | 5366-5369 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
| T334 | 5417-5425 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T335 | 5691-5699 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T336 | 6049-6052 | Disease | denotes | FFA | http://purl.obolibrary.org/obo/MONDO_0016776 |
| T337 | 6360-6372 | Disease | denotes | hypertension | http://purl.obolibrary.org/obo/MONDO_0005044 |
| T338 | 6374-6376 | Disease | denotes | HF | http://purl.obolibrary.org/obo/MONDO_0005252 |
| T339 | 6378-6401 | Disease | denotes | coronary artery disease | http://purl.obolibrary.org/obo/MONDO_0005010 |
| T340 | 6387-6401 | Disease | denotes | artery disease | http://purl.obolibrary.org/obo/MONDO_0000473 |
| T341 | 6403-6406 | Disease | denotes | CAD | http://purl.obolibrary.org/obo/MONDO_0005010|http://purl.obolibrary.org/obo/MONDO_0018922 |
| T343 | 6409-6417 | Disease | denotes | diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
| T344 | 6419-6426 | Disease | denotes | obesity | http://purl.obolibrary.org/obo/MONDO_0011122 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T263 | 134-137 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | arm |
| T264 | 338-343 | http://purl.obolibrary.org/obo/UBERON_0003103 | denotes | organ |
| T265 | 400-405 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T266 | 565-570 | http://purl.obolibrary.org/obo/UBERON_0003103 | denotes | organ |
| T267 | 887-889 | http://purl.obolibrary.org/obo/CLO_0001022 | denotes | Li |
| T268 | 887-889 | http://purl.obolibrary.org/obo/CLO_0007314 | denotes | Li |
| T269 | 1216-1219 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | arm |
| T270 | 1225-1230 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T271 | 1361-1366 | http://purl.obolibrary.org/obo/UBERON_0003103 | denotes | organ |
| T272 | 1420-1424 | http://purl.obolibrary.org/obo/CLO_0053001 | denotes | 1–14 |
| T273 | 1586-1591 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T274 | 1829-1830 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T275 | 2426-2427 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T276 | 2449-2455 | http://purl.obolibrary.org/obo/UBERON_0001005 | denotes | airway |
| T277 | 2497-2498 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | B |
| T278 | 2580-2586 | http://purl.obolibrary.org/obo/UBERON_0001005 | denotes | airway |
| T279 | 3329-3331 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
| T280 | 4302-4312 | http://purl.obolibrary.org/obo/SO_0000418 | denotes | signalling |
| T281 | 5273-5278 | http://purl.obolibrary.org/obo/UBERON_0003103 | denotes | organ |
| T282 | 6387-6393 | http://purl.obolibrary.org/obo/UBERON_0001637 | denotes | artery |
| T283 | 6387-6393 | http://www.ebi.ac.uk/efo/EFO_0000814 | denotes | artery |
| T284 | 6633-6635 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T299 | 224-228 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T300 | 241-254 | Chemical | denotes | dapagliflozin | http://purl.obolibrary.org/obo/CHEBI_85078 |
| T301 | 257-268 | Chemical | denotes | ambrisentan | http://purl.obolibrary.org/obo/CHEBI_135949 |
| T302 | 448-459 | Chemical | denotes | ambrisentan | http://purl.obolibrary.org/obo/CHEBI_135949 |
| T303 | 508-510 | Chemical | denotes | IV | http://purl.obolibrary.org/obo/CHEBI_74327 |
| T304 | 511-520 | Chemical | denotes | Vitamin C | http://purl.obolibrary.org/obo/CHEBI_21241|http://purl.obolibrary.org/obo/CHEBI_29073|http://purl.obolibrary.org/obo/CHEBI_38290 |
| T307 | 511-518 | Chemical | denotes | Vitamin | http://purl.obolibrary.org/obo/CHEBI_33229 |
| T308 | 678-687 | Chemical | denotes | vitamin C | http://purl.obolibrary.org/obo/CHEBI_21241 |
| T309 | 678-685 | Chemical | denotes | vitamin | http://purl.obolibrary.org/obo/CHEBI_33229 |
| T310 | 762-771 | Chemical | denotes | vitamin C | http://purl.obolibrary.org/obo/CHEBI_21241 |
| T311 | 762-769 | Chemical | denotes | vitamin | http://purl.obolibrary.org/obo/CHEBI_33229 |
| T312 | 830-835 | Chemical | denotes | water | http://purl.obolibrary.org/obo/CHEBI_15377 |
| T313 | 887-889 | Chemical | denotes | Li | http://purl.obolibrary.org/obo/CHEBI_30145 |
| T314 | 970-981 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T315 | 1225-1230 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T316 | 1586-1591 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T317 | 1618-1629 | Chemical | denotes | polystyrene | http://purl.obolibrary.org/obo/CHEBI_53276 |
| T318 | 1974-1983 | Chemical | denotes | melatonin | http://purl.obolibrary.org/obo/CHEBI_16796 |
| T319 | 2078-2080 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T321 | 2092-2101 | Chemical | denotes | Melatonin | http://purl.obolibrary.org/obo/CHEBI_16796 |
| T322 | 2340-2342 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T324 | 2419-2425 | Chemical | denotes | Cohort | http://purl.obolibrary.org/obo/CHEBI_34935 |
| T325 | 2490-2496 | Chemical | denotes | Cohort | http://purl.obolibrary.org/obo/CHEBI_34935 |
| T326 | 2544-2549 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T327 | 3009-3011 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T329 | 3057-3059 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T331 | 3128-3130 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T333 | 3163-3174 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T334 | 3652-3654 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T336 | 3688-3694 | Chemical | denotes | Cohort | http://purl.obolibrary.org/obo/CHEBI_34935 |
| T337 | 3790-3796 | Chemical | denotes | Cohort | http://purl.obolibrary.org/obo/CHEBI_34935 |
| T338 | 4049-4055 | Chemical | denotes | Cohort | http://purl.obolibrary.org/obo/CHEBI_34935 |
| T339 | 4093-4099 | Chemical | denotes | Cohort | http://purl.obolibrary.org/obo/CHEBI_34935 |
| T340 | 4137-4143 | Chemical | denotes | Cohort | http://purl.obolibrary.org/obo/CHEBI_34935 |
| T341 | 4297-4299 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T343 | 5112-5120 | Chemical | denotes | Losartan | http://purl.obolibrary.org/obo/CHEBI_6541 |
| T344 | 5181-5189 | Chemical | denotes | Losartan | http://purl.obolibrary.org/obo/CHEBI_6541 |
| T345 | 5301-5309 | Chemical | denotes | Losartan | http://purl.obolibrary.org/obo/CHEBI_6541 |
| T346 | 5356-5364 | Chemical | denotes | Losartan | http://purl.obolibrary.org/obo/CHEBI_6541 |
| T347 | 5442-5450 | Chemical | denotes | Losartan | http://purl.obolibrary.org/obo/CHEBI_6541 |
| T348 | 5575-5583 | Chemical | denotes | Losartan | http://purl.obolibrary.org/obo/CHEBI_6541 |
| T349 | 5630-5651 | Chemical | denotes | Eicosapentaenoic acid | http://purl.obolibrary.org/obo/CHEBI_28364 |
| T350 | 5647-5651 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
| T351 | 5653-5656 | Chemical | denotes | EPA | http://purl.obolibrary.org/obo/CHEBI_28364|http://purl.obolibrary.org/obo/CHEBI_36006 |
| T353 | 5663-5673 | Chemical | denotes | fatty acid | http://purl.obolibrary.org/obo/CHEBI_35366 |
| T354 | 5669-5673 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
| T355 | 5757-5760 | Chemical | denotes | EPA | http://purl.obolibrary.org/obo/CHEBI_28364|http://purl.obolibrary.org/obo/CHEBI_36006 |
| T357 | 5992-5994 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T359 | 6006-6027 | Chemical | denotes | Eicosapentaenoic acid | http://purl.obolibrary.org/obo/CHEBI_28364 |
| T360 | 6023-6027 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
| T361 | 6033-6043 | Chemical | denotes | fatty acid | http://purl.obolibrary.org/obo/CHEBI_35366 |
| T362 | 6039-6043 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
| T363 | 6045-6048 | Chemical | denotes | EPA | http://purl.obolibrary.org/obo/CHEBI_28364|http://purl.obolibrary.org/obo/CHEBI_36006 |
| T365 | 6049-6052 | Chemical | denotes | FFA | http://purl.obolibrary.org/obo/CHEBI_42638 |
| T366 | 6148-6158 | Chemical | denotes | Colchicine | http://purl.obolibrary.org/obo/CHEBI_27882 |
| T367 | 6374-6376 | Chemical | denotes | HF | http://purl.obolibrary.org/obo/CHEBI_141438|http://purl.obolibrary.org/obo/CHEBI_29228 |
| T369 | 6435-6445 | Chemical | denotes | Colchicine | http://purl.obolibrary.org/obo/CHEBI_27882 |
| T370 | 6557-6567 | Chemical | denotes | Colchicine | http://purl.obolibrary.org/obo/CHEBI_27882 |
| T371 | 6662-6672 | Chemical | denotes | colchicine | http://purl.obolibrary.org/obo/CHEBI_23359 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T93 | 4302-4312 | http://purl.obolibrary.org/obo/GO_0023052 | denotes | signalling |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T285 | 0-82 | Sentence | denotes | Pharmacological intervention Sample size and criteria Treatment protocol Reference |
| T286 | 83-99 | Sentence | denotes | • TACTIC-E Trial |
| T287 | 100-154 | Sentence | denotes | • Immunomodulatory agents • Multi-arm randomized trial |
| T288 | 155-204 | Sentence | denotes | • Pre-intensive care unit (ICU) COVID-19 patients |
| T289 | 205-286 | Sentence | denotes | • Immunomodulatory drug EDP1815 vs. dapagliflozin + ambrisentan vs. standard care |
| T290 | 287-423 | Sentence | denotes | • Primary outcome includes need for cardiovascular organ support • EDP1815 as 2 capsules twice daily (1.6 × 1011 cells) for up to 7 days |
| T291 | 424-495 | Sentence | denotes | • Dapagliflozin 10 mg + ambrisentan 5 mg once daily (NCT04393246, 2020) |
| T292 | 496-649 | Sentence | denotes | • High dose IV Vitamin C to ameliorate cytokine storm and associated organ dysfunction • Prospective placebo controlled randomized controlled trial (RCT) |
| T293 | 650-660 | Sentence | denotes | • N = 308 |
| T294 | 661-706 | Sentence | denotes | • High dose i.v. vitamin C (HIVC) vs. placebo |
| T295 | 707-904 | Sentence | denotes | • Primary outcome of ventilator-free days • 12 g/50 ml vitamin C infusion 12 ml/h twice daily for 7 days vs. 50 ml sterile water for injection infused at 12 ml/h (Liu, Zhu, Zhang, Li, & Peng, 2020) |
| T296 | 905-959 | Sentence | denotes | • TOC-COVID Trial • Prospective placebo controlled RCT |
| T297 | 960-1002 | Sentence | denotes | • N = 100 tocilizumab + standard treatment |
| T298 | 1003-1042 | Sentence | denotes | • N = 100 placebo + standard treatment |
| T299 | 1043-1148 | Sentence | denotes | • Primary outcome of ventilation-free days • Tocilizumab 8 mg/kg single i.v. dose (Rilinger et al., 2020) |
| T300 | 1149-1165 | Sentence | denotes | • TACTIC-R Trial |
| T301 | 1166-1236 | Sentence | denotes | • Immunomodulatory agents • Randomized parallel 3-arm open label trial |
| T302 | 1237-1259 | Sentence | denotes | • N = 125 Baricitinib |
| T303 | 1260-1282 | Sentence | denotes | • N = 125 Ravulizumab |
| T304 | 1283-1309 | Sentence | denotes | • N = 125 standard of care |
| T305 | 1310-1424 | Sentence | denotes | • Primary outcome includes need for cardiovascular organ support • Baricitinib 4 mg orally once daily on days 1–14 |
| T306 | 1425-1500 | Sentence | denotes | • Ravulizumab single i.v. weight-based dose regimen (Kulkarni et al., 2020) |
| T307 | 1501-1517 | Sentence | denotes | • CytoResc Trial |
| T308 | 1518-1604 | Sentence | denotes | • Cytokine storm in hyperinflammation and shock • Prospective, open-label, pilot study |
| T309 | 1605-1680 | Sentence | denotes | • ‘CytoSorb’ polystyrene-based hemoadsorber to adsorb circulating cytokines |
| T310 | 1681-1704 | Sentence | denotes | • N = 40–50 ‘CytoSorb’ |
| T311 | 1705-1730 | Sentence | denotes | • N = 40–50 standard care |
| T312 | 1731-1885 | Sentence | denotes | • Primary outcome is time to resolution of vasoplegic shock • ‘CytoSorb’ therapy administered via a shaldon catheter for 3–7 days (Stockmann et al., 2020) |
| T313 | 1886-1940 | Sentence | denotes | • MelCOVID Trial • Double blind placebo controlled RCT |
| T314 | 1941-1964 | Sentence | denotes | • ICU COVID-19 patients |
| T315 | 1965-2002 | Sentence | denotes | • N = 12 melatonin + standard of care |
| T316 | 2003-2043 | Sentence | denotes | • N = 6 placebo control + standard care |
| T317 | 2044-2147 | Sentence | denotes | • Secondary outcome includes CRP, IL-6 levels • Melatonin 5 mg/kg/day i.v. divided every 6 h for 7 days |
| T318 | 2148-2242 | Sentence | denotes | • Placebo dose of 5 mg/kg/day i.v. divided every 6 h for 7 days (Rodriguez-Rubio et al., 2020) |
| T319 | 2243-2332 | Sentence | denotes | • Siltuximab for patients diagnosed with severe respiratory complications due to COVID-19 |
| T320 | 2333-2416 | Sentence | denotes | • Anti-IL-6 mitigation of cytokine storm • Observational retrospective cohort study |
| T321 | 2417-2487 | Sentence | denotes | • Cohort A: continuous positive airway pressure followed by siltuximab |
| T322 | 2488-2533 | Sentence | denotes | • Cohort B: intubation followed by siltuximab |
| T323 | 2534-2614 | Sentence | denotes | • Control group receiving continuous positive airway pressure or intubation only |
| T324 | 2615-2625 | Sentence | denotes | • N = 220 |
| T325 | 2626-2721 | Sentence | denotes | • Primary outcome of mortality over 30 days • Detailed siltuximab dosing regimen not specified. |
| T326 | 2722-2777 | Sentence | denotes | • Treatment procedure was based on clinicians judgement |
| T327 | 2778-2808 | Sentence | denotes | • Study completed May 8, 2020. |
| T328 | 2809-2844 | Sentence | denotes | Results pending (NCT04322188, 2020) |
| T329 | 2845-2860 | Sentence | denotes | • COV-AID Trial |
| T330 | 2861-2938 | Sentence | denotes | • Use of anti-interleukin agents for cytokine storm • Phase 3 prospective RCT |
| T331 | 2939-2978 | Sentence | denotes | • Patients with signs of cytokine storm |
| T332 | 2979-3023 | Sentence | denotes | • N = 38 Anakinra alone (anti-IL-1 receptor) |
| T333 | 3024-3062 | Sentence | denotes | • N = 76 Siltuximab alone (anti-IL-6) |
| T334 | 3063-3094 | Sentence | denotes | • N = 38 Anakinra + siltuximab |
| T335 | 3095-3142 | Sentence | denotes | • N = 76 Tocilizumab alone (anti-IL-6 receptor) |
| T336 | 3143-3174 | Sentence | denotes | • N = 38 Anakinra + tocilizumab |
| T337 | 3175-3203 | Sentence | denotes | • N = 76 standard care alone |
| T338 | 3204-3294 | Sentence | denotes | • Primary outcome as time to clinical improvement • Anakinra 100 mg s.c. daily for 28 days |
| T339 | 3295-3337 | Sentence | denotes | • Siltuximab single i.v. infusion 11 mg/kg |
| T340 | 3338-3411 | Sentence | denotes | • Tocilizumab single i.v. infusion 8 mg/kg max 800 mg (Maes et al., 2020) |
| T341 | 3412-3460 | Sentence | denotes | • Sarilumab for hospitalized COVID-19 infections |
| T342 | 3461-3502 | Sentence | denotes | • Cytokine storm syndrome • Phase 2/3 RCT |
| T343 | 3503-3513 | Sentence | denotes | • Phase 2: |
| T344 | 3514-3591 | Sentence | denotes | Sarilumab in hospitalized patients regardless of disease severity vs. placebo |
| T345 | 3592-3677 | Sentence | denotes | • Primary outcome of % change in CRP in patients with serum IL-6 > upper limit normal |
| T346 | 3678-3697 | Sentence | denotes | • Phase 3 Cohort 1: |
| T347 | 3698-3787 | Sentence | denotes | Sarilumab in hospitalized critical infection receiving mechanical ventilation vs. placebo |
| T348 | 3788-3799 | Sentence | denotes | • Cohort 2: |
| T349 | 3800-3880 | Sentence | denotes | Sarilumab in hospitalized infection receiving mechanical ventilation vs. placebo |
| T350 | 3881-3892 | Sentence | denotes | • N = 1912 |
| T351 | 3893-3979 | Sentence | denotes | • Primary outcome of at least 1 point improvement on 7 point clinical scale • Phase 2: |
| T352 | 3980-4003 | Sentence | denotes | Low dose sarilumab i.v. |
| T353 | 4004-4014 | Sentence | denotes | • Phase 2: |
| T354 | 4015-4038 | Sentence | denotes | Mid-dose sarilumab i.v. |
| T355 | 4039-4058 | Sentence | denotes | • Phase 3 Cohort 1: |
| T356 | 4059-4082 | Sentence | denotes | Low dose sarilumab i.v. |
| T357 | 4083-4102 | Sentence | denotes | • Phase 3 Cohort 1: |
| T358 | 4103-4126 | Sentence | denotes | Mid-dose sarilumab i.v. |
| T359 | 4127-4146 | Sentence | denotes | • Phase 3 Cohort 2: |
| T360 | 4147-4171 | Sentence | denotes | High dose sarilumab i.v. |
| T361 | 4172-4241 | Sentence | denotes | • Placebo given to match sarilumab administration (NCT04315298, 2020) |
| T362 | 4242-4263 | Sentence | denotes | • CORIMUNO-SARI Trial |
| T363 | 4264-4318 | Sentence | denotes | • Sarilumab to mitigate enhanced IL-6 signalling • RCT |
| T364 | 4319-4369 | Sentence | denotes | • Moderate, severe, or critical COVID-19 pneumonia |
| T365 | 4370-4402 | Sentence | denotes | • Sarilumab vs. standard of care |
| T366 | 4403-4491 | Sentence | denotes | • N = 239 • Sarilumab 400 mg single i.v. infusion over 1 h on day 1 (NCT04324073, 2020) |
| T367 | 4492-4571 | Sentence | denotes | • Barcitinib for hospitalized COVID-19 patients • Non-randomized clinical trial |
| T368 | 4572-4634 | Sentence | denotes | • Any adult patient hospitalized with moderate/severe COVID-19 |
| T369 | 4635-4687 | Sentence | denotes | • Barcitinib + standard care vs. standard care alone |
| T370 | 4688-4801 | Sentence | denotes | • Primary outcome of clinical status after 15 days • Barcitinib 2 mg orally daily for 10 days (NCT04321993, 2020) |
| T371 | 4802-4851 | Sentence | denotes | • RUXCOVID Trial • Phase 3 placebo-controlled RCT |
| T372 | 4852-4891 | Sentence | denotes | • Patients age ≥ 12 with cytokine storm |
| T373 | 4892-4949 | Sentence | denotes | • Ruxolitinib + standard care vs. placebo + standard care |
| T374 | 4950-4984 | Sentence | denotes | • N = 402 randomized in 2:1 ratio |
| T375 | 4985-5055 | Sentence | denotes | • treatment: placebo • Ruxolitinib 5 mg orally twice daily for 14 days |
| T376 | 5056-5109 | Sentence | denotes | • May extend treatment to 28 days (NCT04362137, 2020) |
| T377 | 5110-5178 | Sentence | denotes | • Losartan (ARB) in patients hospitalized for COVID-19 • Phase 2 RCT |
| T378 | 5179-5217 | Sentence | denotes | • Losartan vs. placebo + standard care |
| T379 | 5218-5228 | Sentence | denotes | • N = 200 |
| T380 | 5229-5353 | Sentence | denotes | • Secondary outcome includes cardiovascular organ failure/dysfunction • Losartan 50 mg orally once daily (NCT04312009, 2020) |
| T381 | 5354-5439 | Sentence | denotes | • Losartan (ARB) in patients not requiring hospitalization for COVID-19 • Phase 2 RCT |
| T382 | 5440-5478 | Sentence | denotes | • Losartan vs. placebo + standard care |
| T383 | 5479-5489 | Sentence | denotes | • N = 500 |
| T384 | 5490-5627 | Sentence | denotes | • Primary outcome of patients admitted to hospital within 15 days of randomization • Losartan 25 mg orally once daily (NCT04311177, 2020) |
| T385 | 5628-5739 | Sentence | denotes | • Eicosapentaenoic acid (EPA) free fatty acid for hospitalized COVID-19 patients • Phase 3 interventional trial |
| T386 | 5740-5804 | Sentence | denotes | • Treatment with EPA gastro-resistant capsules vs. standard care |
| T387 | 5805-5830 | Sentence | denotes | • 28-day treatment period |
| T388 | 5831-5949 | Sentence | denotes | • Primary outcome of time to treatment failure i.e. need for additional therapy, intubation, transfer to ICU, or death |
| T389 | 5950-6127 | Sentence | denotes | • Secondary outcome includes reduction of IL-6 levels • Eicosapentaenoic acid free fatty acid (EPA-FFA) 1 g gastro-resistant capsules twice daily (2 g total) (NCT04335032, 2020) |
| T390 | 6128-6145 | Sentence | denotes | • COLCORONA Trial |
| T391 | 6146-6266 | Sentence | denotes | • Colchicine and inflammatory cytokine storm • Phase 3 multi-centre placebo-controlled randomized controlled trial (RCT) |
| T392 | 6267-6290 | Sentence | denotes | • Age 40 years or older |
| T393 | 6291-6432 | Sentence | denotes | • Patients must have at least one high-risk factor i.e. uncontrolled hypertension, HF, coronary artery disease (CAD), diabetes, obesity, etc. |
| T394 | 6433-6457 | Sentence | denotes | • Colchicine vs. placebo |
| T395 | 6458-6476 | Sentence | denotes | • 30-day treatment |
| T396 | 6477-6488 | Sentence | denotes | • N = 6000 |
| T397 | 6489-6640 | Sentence | denotes | • Primary composite endpoint of need for hospitalization or death • Colchicine 0.5 mg orally twice daily for 3 days, then 0.5 mg once daily for 27 days |
| T398 | 6641-6707 | Sentence | denotes | • Placebo will match colchicine administration (NCT04322682, 2020) |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T152 | 535-549 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
| T153 | 1520-1534 | Phenotype | denotes | Cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
| T154 | 1560-1565 | Phenotype | denotes | shock | http://purl.obolibrary.org/obo/HP_0031273 |
| T155 | 1785-1790 | Phenotype | denotes | shock | http://purl.obolibrary.org/obo/HP_0031273 |
| T156 | 2359-2373 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
| T157 | 2898-2912 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
| T158 | 2964-2978 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
| T159 | 3463-3477 | Phenotype | denotes | Cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
| T160 | 4360-4369 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
| T161 | 4877-4891 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
| T162 | 6176-6190 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
| T163 | 6360-6372 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
| T164 | 6374-6376 | Phenotype | denotes | HF | http://purl.obolibrary.org/obo/HP_0001635 |
| T165 | 6419-6426 | Phenotype | denotes | obesity | http://purl.obolibrary.org/obo/HP_0001513 |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 33031856-32493514-84038882 | 1143-1147 | 32493514 | denotes | 2020 |
| 33031856-32641154-84038883 | 1495-1499 | 32641154 | denotes | 2020 |
| 33031856-32586396-84038884 | 1880-1884 | 32586396 | denotes | 2020 |
| 33031856-32758298-84038885 | 2237-2241 | 32758298 | denotes | 2020 |
| 33031856-32493441-84038886 | 3406-3410 | 32493441 | denotes | 2020 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1297 | 2073-2076 | Gene | denotes | CRP | Gene:1401 |
| 1298 | 2078-2082 | Gene | denotes | IL-6 | Gene:3569 |
| 1299 | 2340-2344 | Gene | denotes | IL-6 | Gene:3569 |
| 1300 | 3057-3061 | Gene | denotes | IL-6 | Gene:3569 |
| 1301 | 3625-3628 | Gene | denotes | CRP | Gene:1401 |
| 1302 | 3652-3656 | Gene | denotes | IL-6 | Gene:3569 |
| 1303 | 4297-4301 | Gene | denotes | IL-6 | Gene:3569 |
| 1304 | 5992-5996 | Gene | denotes | IL-6 | Gene:3569 |
| 1305 | 2851-2854 | Gene | denotes | AID | Gene:57379 |
| 1306 | 2260-2268 | Species | denotes | patients | Tax:9606 |
| 1307 | 2707-2720 | Species | denotes | not specified | Tax:32644 |
| 1308 | 2847-2850 | Species | denotes | COV | Tax:11118 |
| 1309 | 3540-3548 | Species | denotes | patients | Tax:9606 |
| 1310 | 4531-4539 | Species | denotes | patients | Tax:9606 |
| 1311 | 4584-4591 | Species | denotes | patient | Tax:9606 |
| 1312 | 5130-5138 | Species | denotes | patients | Tax:9606 |
| 1313 | 5374-5382 | Species | denotes | patients | Tax:9606 |
| 1314 | 5511-5519 | Species | denotes | patients | Tax:9606 |
| 1315 | 5700-5708 | Species | denotes | patients | Tax:9606 |
| 1316 | 3632-3640 | Species | denotes | patients | Tax:9606 |
| 1317 | 678-687 | Chemical | denotes | vitamin C | MESH:D001205 |
| 1318 | 762-771 | Chemical | denotes | vitamin C | MESH:D001205 |
| 1319 | 830-835 | Chemical | denotes | water | MESH:D014867 |
| 1320 | 970-981 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 1321 | 1088-1099 | Chemical | denotes | Tocilizumab | MESH:C502936 |
| 1322 | 1248-1264 | Chemical | denotes | Baricitinib • N | |
| 1323 | 1377-1388 | Chemical | denotes | Baricitinib | MESH:C000596027 |
| 1324 | 1420-1438 | Chemical | denotes | 1–14 • Ravulizumab | |
| 1325 | 2245-2255 | Chemical | denotes | Siltuximab | MESH:C504234 |
| 1326 | 2681-2691 | Chemical | denotes | siltuximab | MESH:C504234 |
| 1327 | 3335-3351 | Chemical | denotes | kg • Tocilizumab | |
| 1328 | 4024-4033 | Chemical | denotes | sarilumab | MESH:C000592401 |
| 1329 | 4068-4077 | Chemical | denotes | sarilumab | MESH:C000592401 |
| 1330 | 4112-4121 | Chemical | denotes | sarilumab | MESH:C000592401 |
| 1331 | 4157-4166 | Chemical | denotes | sarilumab | MESH:C000592401 |
| 1332 | 4197-4206 | Chemical | denotes | sarilumab | MESH:C000592401 |
| 1333 | 4416-4425 | Chemical | denotes | Sarilumab | MESH:C000592401 |
| 1334 | 6435-6445 | Chemical | denotes | Colchicine | MESH:D003078 |
| 1335 | 6557-6567 | Chemical | denotes | Colchicine | MESH:D003078 |
| 1336 | 6662-6672 | Chemical | denotes | colchicine | MESH:D003078 |
| 1337 | 187-195 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1338 | 565-582 | Disease | denotes | organ dysfunction | MESH:D009102 |
| 1339 | 911-916 | Disease | denotes | COVID | MESH:C000657245 |
| 1340 | 1947-1955 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1341 | 2291-2316 | Disease | denotes | respiratory complications | MESH:D012131 |
| 1342 | 2324-2329 | Disease | denotes | COVID | MESH:C000657245 |
| 1343 | 2647-2656 | Disease | denotes | mortality | MESH:D003643 |
| 1344 | 3441-3449 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1345 | 3733-3742 | Disease | denotes | infection | MESH:D007239 |
| 1346 | 3826-3835 | Disease | denotes | infection | MESH:D007239 |
| 1347 | 4351-4359 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1348 | 4360-4381 | Disease | denotes | pneumonia • Sarilumab | |
| 1349 | 4522-4530 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1350 | 4626-4631 | Disease | denotes | COVID | MESH:C000657245 |
| 1351 | 4804-4812 | Disease | denotes | RUXCOVID | |
| 1352 | 5156-5164 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1353 | 5258-5286 | Disease | denotes | cardiovascular organ failure | MESH:D002318 |
| 1354 | 5417-5425 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1355 | 5691-5699 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1356 | 6360-6372 | Disease | denotes | hypertension | MESH:D006973 |
| 1357 | 6378-6401 | Disease | denotes | coronary artery disease | MESH:D003324 |
| 1358 | 6403-6406 | Disease | denotes | CAD | |
| 1359 | 6409-6417 | Disease | denotes | diabetes | MESH:D003920 |
| 1360 | 6419-6426 | Disease | denotes | obesity | MESH:D009765 |
| 1361 | 6549-6554 | Disease | denotes | death | MESH:D003643 |